Skye Bioscience Inc
Change company Symbol lookup
Select an option...
SKYE Skye Bioscience Inc
UL Unilever PLC
SF Stifel Financial Corp
NRGD MicroSectors? U.S. Big Oil Index -3X Inverse Leveraged ETNs
BIDU Baidu Inc
ROCR Roth CH Acquisition III Co
BABA Alibaba Group Holding Ltd
ATVI Activision Blizzard Inc
MYNZ Mainz Biomed BV
NURO NeuroMetrix Inc
Go

Health Care : Biotechnology |
Company profile

Skye Bioscience, Inc. is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of cannabinoid-derived therapeutics, with clinical and commercial differentiation for the treatment of glaucoma diseases. The Company’s products programs include THCVHS and CBDVHS. The Company's lead candidate, THCVHS, is a prodrug of tetrahydrocannabinol (THC), is a topical formulation under development for the treatment of glaucoma and ocular hypertension (OHT). It chemically modifies THC to create a unique synthetic molecule with the intent to realize the known positive effects of THC. Its molecule enables enhanced local delivery in the eye, reduced systemic side effects, and the potential for neuroprotection for the treatment of ocular diseases. CBDVHS is a proprietary analog of cannabidiol (CBD) that has demonstrated biological activity that is both pharmacologically and therapeutically distinct from CBD in various preclinical models.

Closing Price
$0.0585
Day's Change
0.0004 (0.60%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.065
Day's Low
0.0536
Volume
(Heavy Day)
Volume:
2,198,358

10-day average volume:
1,720,618
2,198,358

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.